After a busy year of buildouts, Thermo Fisher sets plans for growth in 2023
Last year, Thermo Fisher expanded widely across the US and abroad. This year, however, it’s expecting a big dip in vaccine and therapeutics revenue.
The company brought in $44.92 billion in revenue last year, a growth of 15%, with revenues in the fourth quarter totaling $11.45 billion, a 7% growth from 2021. On the investment call, Thermo Fisher CEO Marc Casper said that its pharma and biotech sector had “impressive performance” with growth in the low teens for the quarter and mid-teens for the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.